CPX-351 in Treating Patients With Relapsed or Refractory High Risk Myelodysplastic Syndrome or Chronic Myelomonocytic Leukemia

NCT03896269 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

38

Enrollment

OTHER

Sponsor class

Conditions

Blasts 10-19 Percent of Bone Marrow Nucleated Cells
Blasts More Than 5 Percent of Bone Marrow Nucleated Cells
High Risk Chronic Myelomonocytic Leukemia
Recurrent Chronic Myelomonocytic Leukemia
Recurrent High Risk Myelodysplastic Syndrome
Refractory Chronic Myelomonocytic Leukemia
Refractory High Risk Myelodysplastic Syndrome

Interventions

DRUG: Liposome-encapsulated Daunorubicin-Cytarabine

Sponsor

M.D. Anderson Cancer Center

Collaborators

[object Object]